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ABSTRACT: Antimicrobial/anticancer peptides (AMPs/ACPs) have
shown promising results as new therapeutic agents in cancer thearpy.
Among them, the designed amphiphilic α-helical peptide G(IIKK)3I-
NH2 (G3) displayed great affinity and specificity in targeting cancer
cells. Here, we report new insights on how G3 penetrates cancer cells.
G3 showed high specificity to HCT-116 colon cancer cells compared
to the HDFs (human neonatal primary dermal fibroblasts) control.
With high concentrations of peptide, a clear cancer cell membrane
disruption was observed through SEM. Gene knockdown of the
endocytic pathways demonstrated that an energy-dependent endocytic
pathway is required for the uptake of the peptide. In addition, G3 can
protect and selectively deliver siRNAs into cancer cells and successfully
modulated their gene expression. Gene delivery was also tested in 3D
cancer spheroids and showed deep penetration delivery into the cancer
spheroids. Finally, the in vivo toxicity of G3 was evaluated on zebrafish
embryos, showing an increasing toxicity effect with concentration.
However, the toxicity of the peptide was attenuated when complexed
with siRNA. In addition, negligible toxicity was observed at the concentration range for efficient gene delivery. The current results
demonstrate that G3 is promising as an excellent agent for cancer therapy.
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1. INTRODUCTION
Cancer is one of the biggest threats to human life. The current
cancer treatment strategies (such as surgery, chemotherapy, and
radiotherapy) are often ineffective and can potentially induce
severe life-threatening side effects. The lack of cell specificity for
chemotherapy is often the main cause for a poor outcome.1,2 In
recent years, novel cancer therapies have been proposed to
improve cell specificity and consequently reduce adverse effects.
Gene therapy is one of the most promising methods for many
cancers due to the defective gene expression in tumor cells.
However, genetic materials often have difficulty passing the
biological barriers, in order to reach the appropriate intracellular
targets.3 Over the years, many approaches (both viral and
nonviral systems) have been trialled to develop effective gene
delivery systems.4−9However, their effectiveness and specificity
are still to be improved.
One of the promising classes of materials for drug/gene
delivery is antimicrobial peptides (AMPs), which has a wide
spectrum of activity not only to pathogens but also to cancer
cells. Therefore, AMPs are the perfect candidates to be
employed as potential new therapeutic and delivery agents.10,11
Most of the AMPs fall in two groups: α-helical and β-sheet
peptides. α-helical AMPs are the most abundant and broadly
studied. They are generally linear with net positive charges
(between +2 and +9) from amino acids such as lysine (K),
arginine (R), and histidine (H), a considerable quantity of
hydrophobic residues (≥30%) such as valine (V), leucine (L),
isoleucine (I), phenylalanine (F), and tryptophan (W), a well-
defined amphipathicity, and a generally small size (normally 6−
50 residues long).12,13 To reduce the toxicity toward host cells,
these peptides often exist in aqueous solution as unstructured
monomers, folding into α-helical structures when in contact
with negatively charged lipid membranes.14,15 This structure
propensity is critical for antimicrobial activity and to lower down
cytotoxicity toward host cells.16 AMPs with anticancer proper-
ties are often referred as anticancer peptides (ACPs).10 The
current anticancer drugs are based on alkylating agents, alkaloids
or antimetabolites, and not only have poor cell selectivity but
also often are deactivated by the cancer cells’ intrinsic resistance
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mechanisms, which rapidly remove them from the cytosol
before they can exerting their actions on the designed
intracellular targets.17 In contrast, ACPs show a much better
cell selectivity and reduced resistance, therefore, have been
increasingly studied as possible novel therapeutics.17 To
improve the cell specificity and the drug delivery efficiency,
new peptide based delivery systems have been developed using
cell penetrating peptides (CPPs) or more specifically tumor
targeting peptides (TPPs).18
G(IIKK)3I-NH2 (G3) is a member of a class of synthetic short
cationic amphiphilic peptides G(IIKK)nI-NH2 (n = 1−4)
containing the repeated sequence IIKK (or IKKI), which
enables the ratio of hydrophobic isoleucine (I) to cationic lysine
(K) residues remaining equal.19 Similar to others α-helical
peptides, G3 remains unfolded in aqueous solution. However,
when interact with the negatively charged DPPG (1,2-
dipalmitoylsn-glycero-3-phosphoglycerol) small unilamellar
vesicles (SUVs), which mimic bacterial and tumor cell
membranes, it adopts the typical α-helical structure.19−21
Previous studies revealed that G3 has excellent antibacterial
activity against both Gram-positive (Bacillus subtilis, Staph-
ylococcus aureus, and MRSA) and Gram-negative (Escherichia
coli and Pseudomonas aeruginosa) but at the same time low
cytotoxicity toward mammalian host.19−22 Recent research also
showed that G3 has cancer cell selectivity with a possible
cytostatic effect against HeLa and promyelocytic leukemia
HL60 and an in vivo growth inhibitory effect on HeLa cells
xenografts in nude mice inducing only a little toxicity to the
murine hosts.23 Therefore, it has been increasingly studied for
antimicrobial and anticancer applications.
In this work, using its cancer cell targeting and membrane
disruption effects, G3 has been explored to be used as the siRNA
delivery carriers. An in-depth investigation was performed to
evaluate the selectivity of G3 peptide toward human cancer and
non-cancer cells, usingHCT-116 (colon cancer cells) as a cancer
cell model and HDFs (human neonatal primary dermal
fibroblasts) as a non-cancer model. The uptake pathways of
the G3 into cancer cells were systematically studied. G3 was
subsequently used to transfect siRNA in 2D cell cultures and in
3D tumor spheroid models. The ability of G3 to function as a
delivery vector for knockdown of ECT2 and PLK1, cancer-
related genes, was also assessed. The results demonstrate that an
energy-dependent pathway is necessary to internalize this
peptide and the specific endocytic pathway which is used in
the uptake was successfully identified using a high content RNAi
screening. Finally, the peptide toxicity was evaluated in vivo on
zebrafish embryos monitoring the animals’ development over a
period of 3 days. Complexes of peptide and siRNA were also
injected in zebrafish to further investigate G3 toxicity. The
current work highlights the efficacy of this small cationic peptide
in targeting cancer cells and its promising future as a delivery
agent in cancer therapies.
2. MATERIALS AND METHODS
2.1. Peptides Synthesis. The peptide G(IIKK)3I-NH2 (G3) was
synthesized using standard Fmoc solid-phase synthesis, from natural L-
amino acids, on a commercial CEM Liberty microwave peptide
synthesizer as described in previous publications.19,23−25 The C-
terminal was amidated at the beginning of the synthesis using a Rink-
amide MBHA resin, while the N-terminal was capped with a glycine
(G) prior cleavage from the resin. The final product was purified by cold
ether precipitation (purity of >95%) as indicated by RP-HLPC andMS
analyses. FITC-G(IIKK)3I-NH2 (FITC-G3) was also synthesized using
the same protocol.26 Stock solutions were prepared by dissolving the
peptides in UHQ water and stored at −20 °C.
2.2. Cell Culture. The human epithelial A431 cancer cells were
obtained from the Centre for Membrane Interactions and Dynamics;
the human HCT-116 colon cancer cells were obtained from the
Department of Oncology & Metabolism; and the primary human
dermal fibroblasts (HDFs) were obtained from the Centre for Stem
Cell Biology, all at the University of Sheffield. Cells were cultured in
DMEM medium (GIBCO, Thermo Fisher Technologies) supple-
mented with 10% heat-inactivated fetal bovine serum (FBS) (Merck)
and 100 U/mL penicillin and 100 μg/mL streptomycin (GIBCO,
Thermo Fisher Scientific) at 37 °C and 5% CO2. The cell lines were
periodically tested for the presence of Mycoplasma with EZ-PCR
Mycoplasma Test Kit (BI, Biological Industries) and authenticated by
STR profiling using the PowerPlex 16 HS PCR amplification kit
(Promega).
2.3. Cell Counting Viability Assay. To evaluate the effect of G3
and FITC-G3 against mammalian cells, the cell counting viability assay
was performed. Briefly, HCT-116 or HDF cells were seeded in a 96 well
plate (Corning) at variable densities, depending on the exposure times
or the cell type, in 90 μL of complete culture medium and incubated at
37 °C. On the following day, 10 μL aliquots of peptide at different
concentrations (6.25−100 μM) were added to the wells and incubated
for further 24, 48, or 72 h. Na2CrO4 (Sodium chromate tetrahydrate,
CAS number: 10034-82-91, Merck) was used as a positive control at
200 μM, while the negative control was represented by the UHQwater.
Cells were fixed in 4% paraformaldehyde solution (Merck) and stained
with 2 μg/mL Hoechst 33342 (Thermo Fisher).
2.4. Cell Selectivity Assay. HCT-116 and HDFs were exposed to
several concentrations of FITC-G3 for 24 h and washed with an acid
buffer (50 mM glycine-HCl, 2 M urea, and 100 mMNaCl, pH 3) prior
to fixation with 4% paraformaldehyde solution. Hoechst 33342 (2 μg/
mL) (blue) was used as nuclear staining, while Cell Mask Orange (0.1×
of working solution) was used as plasma membranes staining (red).
2.5. Cold Assay Experiment. HCT-116 cells were seeded in six
well plates (Corning) at 8 × 105 cells/well and incubated overnight at
37 °C. On the following day, the medium was removed, and the cells
were washed twice in cold PBS (4 °C) to block endocytosis. Cold
complete growthmediumwas added to the wells together with 12.5 μM
FITC-G3. Plates were then left for 30 min in ice. The cells were washed
in cold PBS. Some cells were instead moved back into the incubator at
37 °C for further 3 h. In addition, two different conditions were set up:
cells kept in the original medium containing the peptide, or cells were
washed and incubated with new warm medium but lacking peptide.
Controls were prepared as follows: peptide at the same concentration
was added to cells which were then incubated at 37 °C for 30min or 3 h.
Autofluorescence was detected and subtracted from the background
level using untreated cells. All the cells were fixed and stained in a 4%
paraformaldehyde and 2 μg/mL Hoechst 33342 solution.
2.6. siRNA Transfection Procedure. G3 or FITC-G3 peptides
were complexed in complete culture medium with siRNA molecules at
different cationic/anionic charge (molar) ratios. The commercial red
fluorescent siRNA (siGLO Red Transfection Indicator, Dharmacon),
or the targeting PLK1 and ECT2 siRNAs (ON-TARGETplus,
Dharmacon) were used in the siRNA delivery experiments. siRNA
and peptide concentrations varied between 30 and 75 nM, depending
on the assay, while complexes were prepared with charge ratios between
0.5:1 and 10:1. DharmaFECT1 (Dharmacon) was used as the positive
control for transfection following the manufacturer’s instruction. Wells
with only siRNA addition were prepared as the negative control.
2.7. Cancer Cells Targeting Experiment. HCT-116 and HDF
cells were co-cultured together and transfected with 50 nM of siGLO
using DharmaFECT1 or G3, at different ratios. Briefly, 5 × 103 HCT-
116 and 2 × 104 HDFs cells were seeded on a 96 wells plate. Peptide/
siGLO complexes were then added to the wells. On the next day, the
plate was fixed in 4% paraformaldehyde and stained with Hoechst
33342.
2.8. 3D Spheroids Transfection. A431 and HCT-116 3D
spheroids were prepared for 3D transfection. Briefly, cells were seeded
in round low attachment 96 well plates at a density of 1 × 104 cells/well
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in complete medium and grown for 48 h at 37 °C. Using G3 peptide or
DharmaFECT1, 75 nM siGLO were then transfected into each
spheroid using various ratios of peptide/siRNA (from 0.5:1 to 5:1). On
the next day, the spheroids were fixed in 4% paraformaldehyde solution
and stained with Hoechst 33342 solution before being observed under
the light-sheet microscope.
2.9. Sample Preparation for Scanning and Transmission
Electron Microscopy. For scanning electron microscopy (SEM),
HCT-116 cells were seeded in 12 well plates on glass coverslips at a
density of 3 × 105 cells/well in complete medium and grown for 24 h at
37 °C. On the next day, cells were exposed to different concentrations
of FITC-G3 (0.3, 6.25, and 100 μM) for 24 h. An untreated control was
prepared as well. Samples were fixed with 3% Glutaraldehyde (Merck)
in 0.1 M Sodium Cacodylate (Merck) buffer (pH 7.4) before being
rinsed in the cacodylate buffer and postfixed using 2% aqueous osmium
tetroxide (Merck). Following ethanol and hexamethyldisilazane (HEX)
(Merck) dehydration, samples were dried overnight in 100% ethanol
and examined using a Philips XL-20 SEM at 15 kV. For transmission
electron microscopy (TEM), a mouse monoclonal antibody anti-FITC
labeled with 10 nm gold nanoparticles was used (Aurion, Cat. No.
25583). Briefly, HCT-116 cells were seeded in a 96 well plate at the
density of 2 × 104 cells per well in complete culture medium and
incubated overnight at 37 °C. After 1 day of attachment, the cells were
treated with 6.25 μM of FITC-G3, complexed with the mouse
monoclonal antibody anti-FITC at 1/100 dilution and then added to
cells for either 3 or 24 h. The samples were fixed as a pellet in 4%
paraformaldehyde solution, followed by ethanol dehydration in
proportion 50:50 with the acrylic LR white resin. The samples were
embedded in fresh LR white resin and put in polyethylene capsules
(TAAB, Cat. No. C094). An alternative fixation method was performed
on some samples, to enhance cellular contrast and reduce image
darkness. In this case, samples were fixed using 3% glutaraldehyde in 0.1
M sodium cacodylate buffer (pH 7.4) then washed in the same buffer
and postfixed with 2% osmium tetroxide. Samples were then
dehydrated with ethanol, cleared in epoxypropane (EPP) (CAS
Number 16088-62-3, Merck), infiltrated in 50:50 Araldite resin and
EPPmixture and embedded. Ultrathin sections of approximately 85 nm
thick were cut on a Leica UC 6 ultramicrotome and stained with uranyl
acetate followed by Reynold’s Lead Citrate. Sections were examined
using a FEI Tecnai transmission electron microscope at 80 kV.
2.10. RNAi Screen.HCT-116 cells (2× 103 cells/well) were seeded
in 384 well plates and were reverse transfected with 30 nM of siRNAs
using DharmaFECT1. After 3 days, cells were exposed to 6.25 μM of
FITC-G3 peptide and incubated further 24 h. Cells were fixed in 4%
paraformaldehyde solution and stained with 2 μg/mL Hoechst 33342
solution. Images were acquired with the fluorescent automated wide-
field high-content microscope. The difference in fluorescent intensity
across the plate was analyzed and the data obtained were subsequently
used to calculate the robust Z score of each silenced gene.
A library of siRNAs assay (Supporting Information (SI) Table S1)
development plate 2 (ASD2), specifically designed for genome-wide
RNAi screens, was used for the initial development screen. The plate
used for the focused larger screen instead, was a specific library (SI
Table S2) of Traffic-ome targeting siRNAs designed by Doctor Andrew
Peden and Professor Elizabeth Smythe (Biomedical Science Depart-
ment, Sheffield University).
2.11. Zebrafish Husbandry and Strain. Zebrafish were raised in
the Bateson Centre aquaria (University of Sheffield), fed with Artemia
nauplii and maintained in recirculating system at 28 °C on a constant
14:10 h light cycle. The studies performed on zebrafish and described in
these pages are conformed with the UK Home Office regulations and
under the project license: 40/3408 held by RNW. Embryos were
exclusively obtained from natural spawning and raised at 28 °C.
2.12. Microinjections in Zebrafish Embryos. FITC-G3 peptide,
siGLO red fluorescent siRNA or peptide/siGLO complexes were
injected in 1-cell stage embryos. The peptide was injected in a range
between 6.25 pg and 4 ng per embryo; the fluorescent siRNA was
injected in a concentration range of 20−80 pg per embryo, while the
complexes were made with 20 pg of siGLO and 20 or 80 pg of peptide
per embryo. Several fish batches were used in each experiment and
uninjected embryos were always kept as controls. On average, 80 eggs
per concentration were injected. Live embryos were checked on a Leica
MZ16 stereomicroscope at 1- or 3-days post fertilization (dpf) and the
viability was recorded. Conforming to the UK Home Office regulation,
before reaching 5.2 dpf embryos were anaesthetised using Tricaine (40
mg/L) and sacrificed in a bleach solution.
2.13. Microscopy. Cell counting viability assays and the trans-
fection outcomes of fluorescent experiments were all acquired using the
fluorescent automated wide-field high-content ImageXpress Micro
microscope (Molecular Device) and segmentation analysis performed
using MetaXpress Software 5.3.01 (Molecular Devices). 3D spheroids
images were acquired using the light sheet fluorescent microscope Zeiss
Lightsheet Z.1 and analyzed with the ZEN 2014 SP1 (Zeiss) software.
The cocultured cell system and the cold assay experiments were imaged
using the IN Cell Analyzer 2200 (GE Healthcare) microscope.
Quantification of peptide uptake following cold assay was performed
using the In Cell Developer Toolbox l.9 (GE Healthcare). Images of 3
dpf zebrafish embryos were acquired using a Zeiss Axio Zoom.V16
fluorescence stereomicroscope. ImageJ was used for further image
processing.
3. RESULTS
3.1. In Vitro Cell Toxicity and Specificity. Previous
studies on G3 showed excellent antimicrobial effect and a
Figure 1. High content cell counting assay to evaluate the impact of G3 peptide on non-cancer and cancer models. Number of (a) HDFs (human
dermal fibroblasts) or (b) HCT-116 (colon cancer cells) counted after exposure to increasing concentration of G3 peptide for 24−72 h, normalized to
the relative negative control and expressed as a percentage. The values obtained are averages of independent experiments with at least three replicates
for each experimental point ± standard error mean (±SEM). Na2CrO4 (200 μM) was used as a positive control (data not showed), while water was
used as negative control (0). Statistically significant differences from the negative controls were determined by Student’s t test (*p<0.05; **p<0.01;
***p<0.001).
ACS Applied Materials & Interfaces www.acsami.org Research Article
https://doi.org/10.1021/acsami.1c14761
ACS Appl. Mater. Interfaces 2021, 13, 49713−49728
49715
tangible cytotoxic effect in multiple cancer cell lines (e.g., HeLa,
HepG2, and HL60 cells) but still benign to normal cells such as
dermal fibroblasts.19,22,23 In this study, its toxicity and specificity
were first tested against HDFs and HCT-116, using the cell
counting method. Changes in the total cell number, induced by
reduced proliferation or increased cell death is a direct measure
of cell viability. High content microscopy was used to count cells
in each well of a 96 well plate where cells were exposed to
different peptide concentrations and incubated over a period of
24−72 h. Figure 1a shows the results on primary HDFs. These
results were consistent with the previous work, showing that G3
has very little impact on perturbing the growth of normal human
mammalian cells, even at extremely high concentrations.19,22,23
Figure 1b shows that exposure of G3 on HCT-116 resulted in a
significant decrease in the number of cells, especially after 72 h
and at the highest dose (100 μM). In comparison, previous work
using MTT assay showed a much greater grade of toxicity
toward cancer cells, already visible after 24 h and at much lower
doses than the ones tested in this assay.27−29 The uptake of the
MTT salt in the cells can be variable and it often reflects a
measure of the metabolic activity rather than the cell death. The
difference between the two assays indicates that the peptide
resulted in the cell cytostatic effect at lower peptide
concentrations and at the early stage, while a much higher
concentration is required to result in cell death.30 It is worth
mentioning that the observed peptide toxicity toward HCT-116
cells at certain time points or concentrations is not the focus of
this work, which instead is to assess the ability of G3 to carry
siRNA molecules inside cancer cells. We have also evaluated the
effect of 24 h exposure of FITC-G3 on HCT-116 and HDFs to
determine whether the presence of the fluorophore could have
had an impact on the peptide’s intrinsic cell selectivity. The
results (SI Figure S1) revealed that FITC-G3 behaved similarly
to G3 apart from a slight increase of toxicity toward the normal
Figure 2. Cancer cell selectivity and concentration dependent peptide uptake assay. HCT-116 (a) and HDFs (b) were exposed to several
concentrations of FITC-G3 for 24 h and washed with an acid buffer before fixation. The plasmamembrane was stained by Cell Mask Orange (red) and
the nuclei were stained by Hoechst 33342 (blue). The acid wash removes peptides bound to the cellular membranes and in this instance, therefore, can
be used to evaluate the effective amount of peptides internalized into the cells. The peptide showed clear cancer cell selectivity and internalization.
FITC intensity of HCT-116 (c) and HDF (d) cells before and after acid wash, indicating that peptides were inside the cells rather than on the cell
membrane surface. Bar = 25 μm and all the images are scaled at the same size. Statistically significant differences from the negative controls were
determined by Student’s t test (*p < 0.05; **p < 0.01; ***p < 0.001).
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fibroblasts compared to unlabeled peptides. However, only
significant reduction in cell number was observed with the
highest peptide concentration (100 μM) which was not used in
any of further experiments. This could be caused by the
increased hydrophobicity of FITC-G3 compared to G3.
3.2. Tumour Cell Selectivity of G3 Peptide. FITC-G3
was used to investigate the tumor cell selectivity as shown in
Figure 2. Both HCT-116 andHDFs were exposed for 24 h to the
same range of concentrations of FITC-G3. Prior to fixation,
samples were washed by an acid buffer to remove the peptide
bond on the cellular membranes. The amount of peptide
uptaken by the cells is directly proportioned to the intensity of
green fluorescence observed in each image. HDFs showed very
low green fluorescence intensity, while the HCT-116 showed
strong green fluorescence intensity (Figure 2a,b). The internal-
ization is concentration-dependent and when applying the
highest tested concentration (50 μM), the green fluorophore in
HCT-116 was completely saturated. Figure 2c,d compares the
fluorescence intensity between the HCT-116 and HDF cells.
The former had a much stronger intensity. A similar level of
fluorescence intensity was observed before and after the acid
wash, indicating that most of the peptides were inside the cells
rather than on the cell membrane. SI Figure S2 shows the levels
of peptide uptake at different time points (from 15min to 3 h) in
both cancer and non-cancer cells. Clearly, the peptide showed
excellent cancer cell selectivity and fast internalization into
cancer cells (peptides were already internalized by the cells after
30 min of exposure), while no obvious fluorescence was
observed in HDF cells, at any of the tested time points.
3.3. The Effect of G3 on Cancer Cells. SEM and TEM
were used to better understand and visualize with detail of the
HCT-116 cellular membranes and the internal peptide local-
ization. Figure 3 shows the SEM images of the cancer cells
exposed to 0 (control), 0.3, 6.25, or 100 μM of FITC-G3 for 24
h. 0.3 μM represented the highest peptide dose used for siRNA
transfection. In normal healthy cells, the membranes are covered
in a thin actin plasma membrane, protrusive structures named
filopodia which are essential for sensing the nearby environment.
Filopodia have a pivotal role in cell migration, adhesion
morphogenesis and endocytosis, especially in cancer cells.31
They promote cellular invasion through the tumor micro-
environment and are considered indispensable for driving
cancer cell metastasis and proliferation.32 No evident
modification was observed in cells treated with 0.3 or 6.25 μM
which appeared healthy with membranes enriched in filopodia,
while cells treated with 100 μM not only were reduced in
number (as already illustrated in Figure 1) but also showed
severe signs of deterioration. They also presented a complete
lack of filamentous protrusions. This was even more evident at
higher magnification (Figure 3b), where treated cells had a clear
“spongy”-like phenotype, clearly demonstrating the cell
membrane disruption. From these images, however, it is
impossible to determine peptide internalization.
To further investigate the fate of the internalized peptide in
cancer cells, TEMwas used. To be able to localize the peptide an
antibody (anti-FITC conjugated with 10 nm gold nanoparticles)
was connected to the FITC-G3 before being incubated with the
HCT-116 cancer cells at 6.25 μM of FITC-G3 peptide for 3 or
24 h. then fixed and embedded in resin. Indeed, colloidal gold
nanoparticles, due to their electron density can be easily
recognized on a TEM as dark spherical dots.33,34 Samples
incubated with the antibody-only were considered as negative
controls. Figure 4A−D shows the images of a cancer cell exposed
to a solution of peptide-antibody complexes for 3 h. The yellow
circles indicate the gold nanoparticles visible as dark, electron-
dense spheres. The nanoparticles are found in large vesicles (red
panel) or on the cell membranes (blue and green panels). Figure
4E−J shows images of cells exposed to the same concentration
of peptide for 24 h. Many vesicles of endocytic compartments
full of gold nanoparticles are visible (yellow circle). From E to G
there is a cell with some superficial early endosomes (blue panel)
and some compartments more internally localized (red panel)
which might be late endosomes. From H to J, another cell was
exposed to peptide/antibody complexes with clear signs of
distress. The membrane structures are falling apart, while many
gold nanoparticles are visible (yellow circles) in big vesicles. In
contrast, images of control cells (SI Figure S3) show that both
antibody and peptide are not visible in TEM images if not
complexed together.
3.4. FITC-G3 Uptake Is Driven by an Energy-Depend-
ent Process.A cold assay was performed to investigate if FITC-
G3 peptide uptake was driven by an energy-dependent process.
The idea behind this assay is that if the temperature drops, all the
metabolic active processes in the cells will stop, including the
internalization of particles via endocytosis. Endocytosis is
indeed an energy-dependent process that becomes strongly
inhibited with a decrease in cell temperature.35−37 In the assay,
cells were kept at 4 °C for 30 min and the peptide uptake was
Figure 3. SEM images of peptide treated cancer cell surfaces. (a) HCT-116 cells were exposed to different concentrations (0, 0.3, 6.25, and 100 μM) of
G3 peptide. Bars = 10 μm. (b) Magnified images of control cells (top) and 100 μM peptide treated cells (bottom). Bars = 5 and 1 μm.
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measured as quantification of green fluorescence observed
inside the cells and normalized to control of cells kept at 37 °C
for the same amount of time. Further conditions were tested,
including the evaluation of the recovery of cell metabolism after
the cold thermic shock and the ability of the peptide
internalization. In the first case, the cells following the initial
30 min at 4 °Cwere moved to 37 °C for 3 h and then the peptide
uptake was measured. In the second case, the cells were washed
and replaced with medium without peptide prior to the 3 h
period at 37 °C. In both cases, the quantification of fluorescence
was normalized against a control of cells kept at 37 °C for 3 h.
The imaging and fluorescence quantification (Figure 5) were
Figure 4. TEM images of cancer cells following 3 h (A−D) and 24 h (E−J) exposure to complexes of FITC-G3 and anti-FITC antibody conjugated
with 10 nm Au nanoparticles. HCT-116 cancer cells were exposed to 6.25 μM of FITC-G3 complexed with a mouse monoclonal antibody anti-FITC
conjugated with 10 nm Au nanoparticles (1/100 dilution) and then imaged using TEM. The antibody was used to label the peptide and localize it
inside the cells. (A−D) TEM images show that after 3 h exposure a few Au nanoparticles (yellow circles) are visible in vesicles or in proximity to the
plasma membrane. (E−G) TEM images show that after 24 h exposure many Au nanoparticles (yellow circles) were included in a big endocytic
compartment, possibly endosomes. (H−J) Another cell was exposed to peptide/antibody complexes with many internalized Au nanoparticles (yellow
circles); the cell is severely damaged, and the membrane is falling apart. Bars = 0.2, 0.5, or 1 μm. Images of cells exposed just to the peptide, or the
antibody can be found in SI Figure S2.
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performed using the IN CELL Analyzer microscope and the In
Cell Developer Toolbox l.9 software, respectively. It can be
observed that in a cold environment very little peptide
internalization occurs. However, if the right temperature was
restored, cells can recover and once again, uptake the peptide.
Strikingly, if the medium containing peptide is removed before
restoring the standard culturing conditions, not much peptide
gets internalized. This proved that cells require a warm
environment, and therefore energy, to uptake FITC-G3. In the
absence of an active energy-dependent process, the peptide
alone is unable to stick to the cellular membrane and can be
easily washed away.
3.5. RNAi Screens. The peptide uptake was prevented when
cells were kept at 4 °C, suggesting that an energy-dependent
process (i.e., endocytosis) is necessary for its internalization.
Therefore, we next wondered whether it was possible to identify
which cellular pathway is responsible for FITC-G3 uptake. To
do so, we performed an assay development screening followed
by a wider RNAi high-content screening. The initial assay was
essential to establish the correct experimental conditions such as
cell density and concentration of transfection reagent. A siRNA
library called assay development plate 2 (ASD2), specifically
designed by the Sheffield RNAi Screening Facility was used. The
library was predominantly composed of siRNAs targeting
kinases, but a few were targeting genes related to endocytic
pathways and therefore considered possible “hits” (see Table 1;
for the ASD2 full gene list refers to SI Table S1). HCT-116 cells
were transfected with the siRNAs for 3 days and then incubated
with 6.25 μM of FITC-G3 for a further 24 h. Four different
nontargeting siRNAs (On-TARGETplus nontargeting control
#2, #3, #4, and #5) were used as negative control and their
phenotype considered the standard to be compared with. The
cell density and FITC integrated intensity were subsequently
quantified using theMulti-Wavelength Scoring algorithm within
the MetaXpress software.
The cell counting analysis revealed that, while transfections
made with the nontargeting siRNAs did not interfere with the
cell viability (SI Figure S4), a significant variation in cell number
was observed in several of the functional siRNA (Figure 6a). A
decrease in the cellular growth was encountered for Actr2, Cav1,
Myo5a, and Myo5b where the number of cells was lower than
the negative control. The knockdown of Cltc, Dnm2, Myo5c,
and Rab7a instead did not affect the overall cell population. The
quantification of internalized peptide per cell (Figure 6b,c)
showed a general decrease in uptake, with the exclusion of Actr2
and Rab7a, which maintained levels comparable to the negative
control, and Arf6, for which a significant increase was instead
observed. Arf6 is essential for endosomal recycling in both
clathrin-dependent and independent pathways38 and this latter
observation could imply that not only FITC-G3 is internalized
Figure 5.The peptide uptake is prevented in a cold environment. A cold assay was performed to evaluate FITC-G3 peptide uptake efficiency in cancer
cells under different conditions. HCT-116 cancer cells were exposed to 12.5 μM of FITC-G3 at 37 °C for 30 min (a) and 3 h (b) followed by fixation
(control). (c) HCT-116 cancer cells were exposed to 12.5 μM of FITC-G3 for 30 min in a cold environment (4 °C) followed by fixation (cold + fix).
Some cells from (c) (before fixation) were subsequently incubated for 3 h at 37 °C (cold + incubation) keeping the same medium (d) or replacing the
medium with a fresh one but lacking peptide (e). The graph in (f) shows the quantitative analysis performed to evaluate the level of FITC intensity
observed in the experimental conditions (a−e) and normalized by the controls. The values obtained are averages of independent experiments ±
standard error mean (±SEM). The images complemented by the graph show that the peptide is not internalized by the cells unless a warm
environment is provided, suggesting that the internalization occurs mainly via an active process that requires energy to function. Bar = 25 μm.
Table 1. Genes Selected from the Assay Development Plate 2
As Possible “Hits” for FITC-G3 Peptidea
gene ID function
ACTR2 10097 ATP-binding component of the Arp2/3 complex involved
in the regulation of actin polymerization39
ARF6 382 GTP-binding protein involved in protein trafficking. It
regulates endocytic recycling and cytoskeleton
remodelling38
CAV1 857 scaffolding protein within caveolar membranes40
CLTC 1213 clathrin heavy chain protein. One of the components of a
polyhedral structure of coated pits and vesicles which
entrap specific macromolecules during receptor-mediated
endocytosis41
DNM2 1785 GTP-binding protein associated with microtubules and
implicated in endocytosis and cell motility42
MYO5A 4644 class of actin-based motor proteins involved in cargoes
transport endocytic vesicular trafficking and endosomes
recycling in neuronal and epithelial cells43,44
MYO5B 4645
MYO5C 55930
RAB7A 7879 the key regulator in endolysosomal trafficking and in the
early to-late endosomal maturation45
aGene name, NCBI entrez gene IDs and gene function are listed.
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via endocytosis, but also that, in physiological conditions, it is
recycled back on the cell surface.
For the high content genome screen, a library containing
more than 200 siRNAs targeting genes involved in endocytosis
was used (see SI Table S2 for the complete list). The data
obtained were normalized using the robust z-score method (Z =
(Xi-median)/MAD) which uses median and median absolute
deviation (MAD) instead of mean and standard deviation. The
possible hits were identified in the outliers scoring ≤ −3.5 or ≥
+3.5 z-scores (Figure 6d). The identified hits were 31 (see Table
2); Use1, Rin2, and Copa gave very high z-scores compared to
the rest of the distribution: 39 029, 34 535, and 24 672
respectively (Figure 6d,e). Rin1 scored the highest, with
104 479, which is also reflected by the correspondent picture
in Figure 6e. The peptide completed saturated the cytoplasm of
the cells also affecting their viability. The predictive interactions
between these hits have been graphically represented using
STRING 10.5 database (Figure 6f). We can observe two big,
Figure 6.High-content RNAi targeted screen was performed to investigate the endocytic pathways involved in the uptake of FITC-G3 in HCT-116.
(a−c) Before conducting the high-content RNAi screen, an assay development screening was performed. The cancer cells were transfected with
nontargeting siRNAs or endocytosis-related siRNAs prior to exposure to 6.25 μM of the fluorescent peptide. (a) Number of cells counted after RNAi
knock-down, normalized to the negative control (nt), and expressed as a percentage (%). (b) FITC fluorescence intensity per cell evaluated in HCT-
116 cells following RNAi knock-down, normalized to the negative control (nt) and expressed as a percentage (%). In both graphs, the negative controls
correspond to cells transfected with non-targeting (nt) siRNAs (average of 4 different siRNAs). (c) Images of the cells represented in (a,b) showing the
level of peptide uptake according to the different siRNA transfection. A control image of not transfected cells but exposed to 6.25 μMof the peptide is
represented as well as a control. Following the same transfection procedure adopted for the assay development, an RNAi genome screen was then
performed and the robust Z-score was used to normalize the data obtained. (d) Graphical representation of the RNAi screen output with the
distribution of Z-scores across the whole library. (e) Images of cells in which Rin1, Use 1, Rin 2, andCopa were knocked down. The level of green FITC
fluorescence intensity was much higher compared to the control (non-targeting siRNAs). (f) Schematic representation of the interactions between the
hits found in the screen using String 10.5 to create an interactive map. (g) Schematic representation of the hits main functions in the cell endocytosis.
Legend: N = nucleus; ER = endoplasmic reticulum. All the images are scaled at the same size. In all the images nuclei were stained with Hoechst 33342
(2 μg/mL). Bar = 25 μM. The values obtained are averages of independent experiments with at least three replicates for each experimental point ±
standard error mean (±SEM). Statistically significant difference from the negative controls was determined by Student’s t test (*p < 0.05; **p < 0.01;
***p < 0.001).
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interconnected clusters: one regarding endocytic recycling
pathways and the other one related to vesicles transport
between secretory compartments, mainly associated with the
Golgi network, associated with the recycling pathways cluster we
found Rin 1, Rin 2, and Rin 3. These proteins are Guanine
Nucleotide Exchange Factors (GEFs) for Rab proteins and are
involved in many biological functions including cell growth,
differentiation and receptor mediated endocytosis.46 Moreover,
components of the Rab family, the largest group of Ras
superfamily of monomeric G proteins which are involved in
vesicle trafficking were found as hits: Rab5b, RabGEF1, Rab4a,
Rab4b, and Rab11FIP5.47−50
3.6. Targeted siRNA Delivery into Cancer Cells Using
FITC-G3. RNAi is a great mechanism to alter gene expression
and has proven to be very successful in silencing specific genes.
However, despite having potentially good therapeutic agents,
siRNAs have still very little use in clinical drug development
because of their inability to show cell-type-specific cytosolic
delivery.51,52 Therefore, due to both its cationicity and ability to
preferentially enter cancer cells, we next asked if G3 was able to
bind to negatively charged molecules and transport them only
into target cells. We compared the transfection efficiency of the
commercial reagent DharmaFECT1 (DF1), and either the
peptide G3 or its fluorescent version, FITC-G3. HCT-116 colon
cancer cells and HDFs were the cell lines of choice to
demonstrate G3 specificity.
Figure 7a,b show the transfection of 75 nM of siGLO, a red
fluorescently non-targeting siRNA, via DF1 or via progressively
higher charge ratios of G3. For both cell lines, DF1 had a
Table 2. Complete List of the Hits in the High-Content
Genome Screen, Identified As Outliers Scoring ≤ −3.5 or ≥
+3.5 z-scores
gene z-score gene z-score gene z-score
STXBP1 3646 STX19 7248 VCP 11 372
ARF6 3769 STX12 7660 RAB4B 11 836
BET1L 3838 GAF1 7839 DAB2 12 040
GOSR1 3969 RAB4A 7866 AP2A2 12 710
NSF 4263 VTI1B 8237 AP2B1 13 842
IHPK3 4604 SNAP25 9150 RABGEF1 15 778
STX6 4844 WASF3 9153 COPA 24 672
RAB5B 5716 ARFIP2 9312 RIN2 34 535
STX16 6389 DNM3 10 880 USE1 39 029
YKT6 6462 RIN3 11 130 RIN1 104 479
ADAM10 7149
Figure 7. siRNA delivery into cancer and non-cancer cell models. HCT-116 (a) and HDFs (b) were transfected with 75 nM of siGLO red fluorescent
siRNA with increased charge ratios of G3 peptide. HCT-116 and HDFs were also cocultured (c) and transfected with 50 nM of siGLO red using
DharmaFECT1 or G3 peptide at two different ratios (0.5:1 and 3:1). In the corresponding images, yellow arrows and lines indicate the fibroblasts,
while the green arrows and lines indicate the colon cancer cells. Nuclei were stained with Hoechst 33342. Bars = 25 μm.
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Figure 8. siRNA delivery into cancer cell spheroids. (a) Fluorescent wide-field microscope images of A431 and HCT-116 cancer cell spheroids
transfected with 75 nM of siGLO using DharmaFECT1 (positive control) or G3 peptide. (b) Images of HCT-116 spheroids transfected with 75 nM
siGLO using DharmaFECT1 or G3 peptide at 2:1 ratio and acquired using light-sheet microscopy. The first images on the top left corners are 3D
reconstructions, while the others are sagittal views with combined or separated blue (DAPI) and red (cy3) fluorescent channels. (c) Orthogonal views
of (b) images showing DharmaFECT1 (on the left) and G3 (on the right) transfected spheroids with the location of red siGLO puncta in x, y, z planes.
Nuclei were stained with Hoechst 33342. Bars = 250 μM.
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consistently high efficiency transfection level (even higher in
HDFs), while the peptide showed good levels only toward the
cancer cells (Figure 7a). Most of HCT-116 cells have punctate
cytoplasmic fluorescence, indicating that a reasonable amount of
siRNA had been internalized. However, in HDFs, it is noticeable
that, at any tested ratio, only few red dots are visible (Figure 7b).
The transfection efficiency of FITC-G3 was also evaluated (SI
Figure S5). Similarly, HCT-116 and HDFs were transfected
using different ratios of the peptide. This time, because the
peptide is FITC labeled, it was possible to observe the presence
of both siRNA and peptide in the transfected cells. The yellow
color of the puncta resulted from the overlap of the red (siRNA)
and green (FITC) fluorescent signals. We can hypothesize that
they are colocalized in the same cellular compartment. FITC-G3
behaved like its non-labeled version, showing a preference in
transfecting cancer cells when compared to the HDFs. It is
important to underline that all the concentrations of the peptide
used for these experiments were below the toxic range identified
in Figure 1, even at the highest ratios used with FITC-G3, (24:1)
where 1.2 μM of the peptide was complexed with 50 nM of
siRNA.
Finally, we evaluated the ability of G3 in selecting cancer cells
if a more physiological environment was provided. HCT-116
and HDFs were cocultured and the cells were simultaneously
transfected with 50 nM of siGLO using DF1 or three different
ratios of peptide (Figure 7c). The images shown were acquired
in both fluorescent and brightfield modes and then merged to
better visualize the cells and their boundaries. Yellow circles and
arrows indicate the fibroblasts, while green circles and arrows are
underline the cancer cells. When the transfection was made
using DF1, an even distribution of siGLO among both cell types
was observed, whereas, when the peptide was used instead, the
siRNA was mainly found within the cancer cells. This important
set of experiments confirmed that G3 has a peculiar selectivity
for cancer cells which can be further exploited.
3.7. G3 Also Delivers siRNAs into 3D Cancer Models.
Following the promising results obtained with G3 on 2D
cultures, we decided to further investigate the peptide
transfection efficiency in a more complex environment: a 3D
tumor spheroid model. The ability to penetrate deeply into a
solid tumor is a quality that a good carrier for either drug or gene
delivery should always have. HCT-116 colon cancer cells and
A431 epithelial cancer cells were cultured in ultralow attachment
plates to generate spheroids and then transfected with 75 nM of
siGLO using DF1 or different peptide ratios (either 2:1 or 5:1).
As a negative control, siRNA alone was added to the spheroids.
Figure 9. Gene knock-down in cancer cells. (a) Cell counting of A431 epithelial cancer cells after transfection with 30 nM of ECT2 siRNA using G3
peptide at different charge ratios (from 0.5:1 to 5:1). DharmaFECT1 was used as positive control, while the addition of siRNA only represented the
negative control. (b) Images of the cells counted in and expressed in graphical form in (c) showing the effects of PLK1 siRNA successful transfection. In
the top left corner, the cells were exposed to the highest concentration of peptides used to transfect the cells (300 nM). Nuclei were stained with
Hoechst 33342. Bars = 25 μM. (c) Cell counting of HCT-116 cancer cells after transfection with 30 nM of PLK1 siRNA using FITC-G3 peptide at
different charge ratios (from 1:1 to 10:1). DharmaFECT1 was used as positive control, while transfection of red fluorescent siGLO represented the
negative control. In both (a) and (c), data were normalized to the relative controls and expressed as a percentage. The values obtained are averages of
independent experiments and with at least three replicates for each experimental point ± standard error mean (±SEM). Statistically significant
differences from the negative controls were determined by Student’s t test (*p < 0.05; **p < 0.01; ***p < 0.001).
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From the preliminary observation under the wide-field micro-
scope, A431 spheroids appeared generally asymmetrical and
differently sized while the ones made with HCT-116 were more
compact, spherical and had an average size of 600−800 μm
(Figure 8a). Due to their more appropriate shape, HCT-116
spheroids were also imaged using light-sheet microscopy
(Figure 8b-c). This allowed us to evaluate the depth in
transfection obtained with the peptide and compare it with
the commercial DF1. The clear visible difference between the
images in Figure 8b,c is the distribution of the red siGLO across
the spheroids’ area. When transfection with DF1 occurred, the
fluorescence of the siRNA was exclusively located on the
spheroid’s surface, whereas, when G3 was used, the siRNA was
uniformly distributed across the whole volume of the spheroid.
This could be nicely appreciated with the 3D reconstructions,
both the sagittal and orthogonal views were elaborated with
ZEN 2014 SP1 (Zeiss) software. In the orthogonal view, blue,
red, and green lines, which represent respectively the x, y, z
planes, display the localization of single red puncta in a 3D
spatial distribution.
3.8. Effective Cancer Genes Knock-down Using the
Peptides as siRNA Carriers. Following all the promising
results obtained with G3 in transfecting non-targeting siRNAs
into 2D and 3D cultures of cancer cells, two functional siRNAs
Figure 10. In vivo toxicity of the peptide and complexes using a Zebrafish model. (a) Embryos counting at 1- or 3-days post fertilization (dpf) following
microinjections with FITC-G3 peptide between 6.25 and 4000 pg. (b) Embryos counting at 1- or 3-dpf following microinjections with the red
fluorescent siRNA siGLO between 20 and 80 pg. (c) Embryos counting at 1- or 3-dpf following microinjections with 20 pg of siGLO complexed with
FITC-G3at 1:1 or 4:1 charge ratio. The toxicity of the peptide is significantly decreased when complexed with a cargo. (d) Images acquired with a
fluorescent microscope of 3-dpf embryos microinjected with increasing concentrations of siGLO showing the siRNA distribution. (e) Images of 3-dpf
embryos injected with peptide/siGLO complexes showing the distribution of the fluorescent siRNA and peptide in the body of the embryo. Bars = 500
μM.
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targeting ECT2 (Epithelial Cell Transforming 2 oncogene) and
PLK1 (Polo-Like Kinase 1) were transfected into cancer cells.
Depletion of these two genes by RNAi induces the arrest of the
cell cycle and consequent apoptosis, which can be easily
quantified as a decrease in cell numbers.53,54
The 30 nM of ECT2 siRNA was transfected in A431 cells
using G3 while 30 nM of PLK1 was transfected in HCT-116
using FITC-G3. DF1 transfection performed in parallel was
considered as a positive control. In the ECT2 siRNA
transfection, the uncomplexed siRNAs diluted in the culture
medium was used as the negative control. In the PLK1 siRNA
transfection instead, the transfection of the red siGLO was
considered as the negative control. In both sets of experiments,
the number of cells was counted three days after transfection and
then normalized to their relative negative controls. The graph in
Figure 9a shows the cell number for ECT2 siRNA transfection
cells using G3 at different ratios or DF1. the DF1, as expected,
had a reasonable degree of knockdown (−75% in cell
population). The peptide also, apart from the smaller ratio,
showed a significant decrease in cell number (−50% in cell
population) consistent with a successful RNAi. Interestingly,
little difference was observed across the various ratios used after
1:1.
The graph in Figure 9c instead shows the cell count following
transfection of PLK1 siRNA in HCT-116 using FITC-G3 or
DF1. The usage of DF1 as a delivery agent significantly
decreased the cell population by 65%. It is worth noting that the
transfection with FITC-G3 was more efficient than unlabeled
G3, at every ratio, the cell number decreased by 80% compared
to the control. This can be a result of a minor increase in
hydrophobicity in FITC-G3 as a result of adding the FITC
molecule to the peptide structure.55 Since the fluorescent siRNA
and peptide were used as the negative control and delivery agent,
it was possible to observe at higher magnification the presence of
the peptide inside the cells at the higher ratio used (10:1
corresponding to 300 nM) or once again the colocalization of
siGLO and peptide as yellow cytoplasmic puncta in the negative
control (Figure 9b). To ensure that the concentrations of
peptide used in this experiment did not impact the cell viability,
the control experiment was performed using 300 nM of peptide
(first image in the top left corner). No signs of toxicity were
visible, with the number of cells that showed to be 103%
compared to the negative control.
3.9. In Vivo Toxicity Study.Zebrafish embryos were used as
the chosen in vivomodel to evaluate the toxicity of the FITC-G3
peptide. Embryos in the single-cell stage were microinjected
with the peptide. Concentrations in the range of 3 μM to 2 mM
(corresponding to 0.065−4 ng/embryo) were chosen to
investigate the toxicity of FITC-G3during the embryonic
development of zebrafish. From Figure 10a, it was observed
that all the tested concentrations, apart from 6.25 pg significantly
reduced the number of alive embryos scored at 1- or 3-days post
fertilization check-points. A little variation is observed between
the two time points suggesting that the peptide toxicity is more
severe in the initial phases of embryogenesis. It is worth
highlighting that despite the evident poor viability, the
concentrations used for our transfection experiments were
more than 10 times lower than 6.25 pg.
The fluorescent siRNA siGLO and its complexes of FITC-G3
peptide were also injected in zebrafish embryo at the single-cell
stage to evaluate the change in peptide toxicity when used as
cargo carrier inside the fish. Prior to complexation, siGLO
toxicity was initially evaluated in zebrafish embryos. According
to literature, injections of 100 pg or more of siRNA or DNA
would kill most of the embryos.56,57 For this reason, a range of
siRNA concentrations between 20 pg and 80 pg per embryo was
tested. The nonfunctional siGLO siRNA was used as the
peptide’s cargo to investigate whether the toxicity observed in
Figure 10a reduces or not. Figure 10b shows the results obtained
from the viability assay performed on 1- or 3-days post
fertilization embryos. High concentrations of siGLO (60 or 80
pg) induced acute toxicity, while 20 and 40 pg of siRNA caused a
very mild effect. Therefore, 20 pg were selected as a suitable
amount for complexation with FITC-G3 peptide. Figure 10d
shows zebrafish embryos at 3-dpf injected with the different
concentrations of siRNA. The intensity in red fluorescence can
be directly related to the amount of siRNA injected.
The peptide was complexed with 20 pg of siGLO at two
different ratios (1:1 or 4:1, corresponding to 20 and 80 pg of
peptide) and the toxicity was carefully evaluated at the usual
checkpoints (1- or 3-dpf embryos). Since 20 pg of siGLO are not
inducing toxicity to the embryos we can assume that any
decreased in the survival rate can be related only to the peptide.
For both tested ratios, the toxicity of the peptide did not reach
50% and it appears to be stable across the two checkpoints
(Figure 10c). Comparing this data to the results in Figure 10a,
the complexes showed a considerable reduction in the peptide
toxicity toward the zebrafish embryos. For example, 20 pg of
FITC-G3 when complexed to siGLO, resulted in an increase in
the viability of the embryos by 40% (same result on day 1 and
day 3), while a similar concentration of free peptide (25 pg)
caused the death of 70% of embryos at 1 dpf which then reached
76% by the third day. With the higher amount of peptide was
used in the 4:1 ratio, the difference between the complexed and
free peptide toxicity was even bigger: A viability of 65% (Figure
10c) was recorded (same result for day 1 and day 3). While at
62.5 pg peptide, the closest concentration of the free peptide,
instead had a higher toxic effect with a decrease in viability of
80% at day 1 which then, by day 3, increased to almost 90%
(Figure 10a). These results demonstrate that, when the peptide
is complexed with the siRNA, its toxicity is significantly reduced,
probably due to a charge neutralization effect.
4. DISCUSSION
Cell-penetrating peptides (CPPs) are one of the main recent
developments in drug and gene delivery. Typically, short (<30
amino acids) CPPs can be obtained from natural proteins or by
rational design and synthesis of peptide sequences to obtain
desirable properties. Recent biomedical studies on hundreds of
CPPs showed that these peptides can be the next generation of
anticancer agents and can be utilized as vectors for gene
delivery.58 The latest research demonstrated that G3 does not
only have antibacterial and anticancer activity but also have
cancer cell specificity.29These unique properties make G3 a very
promising peptide in cancer therapy. However, it is essential to
fully understand the G3′s mechanism of action and uptake
pathways in cancer cells to enhance its application and improve
the design of similar peptides. In addition, it is very promising
that G3 can serve as a vector for small drug molecules and
genetic material delivery, which has not been reported yet. In
general, exerting the required anticancer effect or delivering a
loaded cargo start with internalizing the peptide into the target
cell. There are two main uptake mechanisms: (i) energy-
independent pathways (direct penetration) and (ii) energy-
dependent pathways (endocytosis).59 Most cellular uptake
studies investigate the direct penetration which requires a
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positively charged peptide that interacts with the negatively
charged cellular membrane.23,59 So far, the design and
evaluation of peptides were mainly based on optimizing the
peptide charges, amphipathicity, and the size of the hydro-
phobic/hydrophilic domain.10 These properties are involved in
the destabilization of the membrane associated with peptide
folding on the lipid membrane.22,60−63 For example, the
selectivity of G3 to cancer cells and bacteria has been previously
correlated to the composition and structure of this peptide,
which consists of Gly at the N-terminus and amidation at the C-
terminus.19 Despite the conclusions drawn from previous
studies, the mechanism by which the peptide enters the cells
and cause an effect remains unclear. Although the peptide
interaction with the cell membrane is a key factor in peptide
cellular uptake, other essential factors, such as energy-dependent
pathways, play an important role in peptide uptake and activity.
Our work investigated the mechanism and conditions of cellular
uptake from different perspectives, to have a better insight into
the mechanism of peptide-assisted gene delivery and the
selective anticancer activity of the peptide. In agreement with
a previous study on Hela cancer cells,19 G3 exhibited
concentration-dependent cell selectivity, showing a great affinity
for HCT-116 colorectal cancer cells without having significant
impact on normal cells (HDFs). Our results also showed that the
peptide is mainly uptaken by endocytosis and not by direct
penetration, when a low concentration was used (6.25 μM).
However, as a result of the peptide uptake, the number of
filopodia in the cancer cells treated with 100 μM reduced
massively, with severe signs of deterioration. This can be a result
of direct penetration, disruption, and unfolding in the cell
membrane by the peptide which is responsible for the selective
toxicity in cancer cells. These findings show that this amphiphilic
peptide behaves similarly to other primary hydrophobic
peptides that are usually uptaken by endocytosis at low
concentration and by direct penetration at high concentra-
tion.61,64,65 It is also worth noting that the concentration
threshold for direct penetration varies from one cell line to
another and from one peptide to another.59 The ability of G3 in
entering cancer cells utilizing two differentmodalities is certainly
an important property that should be further studied. Identifying
the biological pathways involved in cellular internalization of the
peptide and the impact of the peptide concentration on the
cancer cells, are important for understanding the effect of the
peptide on cancer cells and for using it as a nonviral vector for
the delivery of genetic materials. By performing RNAi screening,
31 genes involved in the endocytosis of G3 were identified.
These hits revealed that vesicles transport and endocytic
recycling pathways are part of the uptake process in cancer
cells. The cationic nature of the peptide was exploited in this
study to deliver negatively charged siRNAs to target cells. By
evaluating the transfection efficiency of siGLO in cancer cells
(HCT-116) and normal cells (HDFs) using a commercial
reagent (DF1) or G3, the peptide did not only demonstrate high
transfection efficiency, but also high selectivity to cancer cells
while the peptide concentration was below the toxic levels (0.3
μM for the highest peptide: siRNA ratio). In contrast, DF1,
although showed high transfection efficiency, no cancer cell
specificity was observed. In 3D cell culture, G3 significantly
enhanced the penetration of siGLO into HCT-116 spheroids in
comparison DF1 which allows only for transfection on the outer
surface of the spheroids. When targeting siRNAs (e.g., ECT2,
PLK1) were used, the peptide was still able to successfully
deliver both to the target cells. However, the transfection
efficiency of the peptide was either lower (ECT2 to A431) or
higher (PLK1 to HCT-116) than DF1 in cells. This variation in
gene delivery could be associated with the differences in
biological properties of the two cell lines utilized; epithelial from
an epidermoid carcinoma with abnormal expression of
Epidermal growth factor receptor (EGFR) and no functional
copy of p53 (A431), or epithelial from a colorectal cancer with a
mutation in the proto-oncogene KRAS (HCT-116). Our work
opens the doors to new protocols for investigating the anticancer
activity, selectivity, and efficiency in gene delivery of peptides.
The previous studies correlated these properties to the
molecular structure of the peptide and exclusively studied its
interaction with cellular membrane.23,63 To consider this
generation of short amphiphilic peptides for clinical applica-
tions, interdisciplinary work must be conducted to fully study
the peptide from different angles including physical properties,
transfection efficiency in different cell lines, cellular uptake
mechanisms, specificity as well as its behavior in 3D cell culture
and in vivo. Although further studies should be combined with
the presented findings to obtain a complete picture about the
anticancer activity of G3 and its application in gene delivery, this
study bring us a step closer to the goal.
5. CONCLUSIONS
In summary, we have shown that the designed amphiphilic α-
helical peptide G3 not only have an anticancer effect but also can
selectively transfect cancer cells and 3D spheroids with siRNA.
Transfection of the siRNA ECT2 and PLK1 in A431 and HCT-
116 cancer cells was successful, indicating that G3 can modulate
gene expression in cancer cells. We also identified, using high
content RNAi screening, an energy-dependent endocytic
pathway as a possible mechanism of entry of G3 into cancer
cells. Finally, G3 toxicity test on zebrafish embryos gave
important information on the peptide bioavailability and
confirmed its potential for further in vivo studies. Overall, this
work provides new insight into the usage of G3 cell-penetrating
peptides as innovative therapeutics anticancer agents.
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